+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Global Anti-Malarial Medicines Market 2020-2024 - Product Image

Global Anti-Malarial Medicines Market 2020-2024

  • ID: 5011320
  • Report
  • March 2020
  • Region: Global
  • 120 pages
  • TechNavio
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 4

Enquire about COVID-19 updates for this product.

Enquire Now

FEATURED COMPANIES

  • AstraZeneca Plc
  • Bayer AG
  • Cipla Inc.
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline Plc
  • Mylan NV
  • MORE
Global Anti-malarial Medicines Market 2020-2024

The publisher has been monitoring the anti-malarial medicines market and it is poised to grow by $ 310.75 mn during 2020-2024 progressing at a CAGR of 6% during the forecast period. The reports on the anti-malarial medicines market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current global market scenario, latest trends and drivers, and the overall market environment. The market is driven by the strong funding to eradicate malaria, growing incidence of malaria, and robust pipeline and recent drug approvals. In addition, strong funding to eradicate malaria is anticipated to boost the growth of the market as well.

The anti-malarial medicines market analysis include product segments and geographic landscapes.

The anti-malarial medicines market is segmented as below:

By Product
  • Artemisinin compounds
  • Quinolines and related compounds
  • Other compounds
By Geographic Landscape
  • APAC
  • Europe
  • MEA
  • North America
  • South America
This study identifies enhanced POC diagnostics and biomarkers for malaria as one of the prime reasons driving the anti-malarial medicines market growth during the next few years.

The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters.

The anti-malarial medicines market covers the following areas:
  • Anti-malarial Medicines Market sizing
  • Anti-malarial Medicines Market forecast
  • Anti-malarial Medicines Market industry analysis
The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading anti-malarial medicines market vendors that include AstraZeneca Plc, Bayer AG, Cipla Inc., F. Hoffmann-La Roche Ltd., GlaxoSmithKline Plc, Mylan NV, Novartis AG, Pfizer Inc., Sanofi, and Sun Pharmaceutical Industries Ltd.. Also, the anti-malarial medicines market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast an accurate market growth.
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • AstraZeneca Plc
  • Bayer AG
  • Cipla Inc.
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline Plc
  • Mylan NV
  • MORE
Executive Summary
  • Market Overview
Market Landscape
  • Market ecosystem
  • Value chain analysis
Market Sizing
  • Market definition
  • Market segment analysis
  • Market size 2019
  • Market outlook: Forecast for 2019 - 2024
Five Forces Analysis
  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition
Market Segmentation by Product
  • Market segments
  • Comparison by Product
  • Artemisinin compounds - Market size and forecast 2019-2024
  • Quinolines and related compounds - Market size and forecast 2019-2024
  • Other compounds - Market size and forecast 2019-2024
  • Market opportunity by Product
Customer landscape
  • Overview
Geographic Landscape
  • Geographic segmentation
  • Geographic comparison
  • APAC - Market size and forecast 2019-2024
  • MEA - Market size and forecast 2019-2024
  • South America - Market size and forecast 2019-2024
  • Europe - Market size and forecast 2019-2024
  • North America - Market size and forecast 2019-2024
  • Key leading countries
  • Market opportunity by geography
Drivers, Challenges, and Trends
  • Market drivers
  • Market challenges
  • Market trends
Vendor Landscape
  • Overview
  • Landscape disruption
Vendor Analysis
  • Vendors covered
  • Market positioning of vendors
  • AstraZeneca Plc
  • Bayer AG
  • Cipla Inc.
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline Plc
  • Mylan NV
  • Novartis AG
  • Pfizer Inc.
  • Sanofi
  • Sun Pharmaceutical Industries Ltd.
Appendix
  • Scope of the report
  • Currency conversion rates for US$
  • Research methodology
  • List of abbreviations
List of Exhibits
1. Key Finding 1
2. Key Finding 2
3. Key Finding 3
4. Key Finding 5
5. Key Finding 6
6. Key Finding 7
7. Key Finding 8
8. Parent market
9. Market characteristics
10. Offerings of vendors included in the market definition
11. Market segments
12. Global - Market size and forecast 2019 - 2024 ($ million)
13. Global market: Year-over-year growth 2019 - 2024 (%)
14. Five forces analysis 2019 & 2024
15. Bargaining power of buyers
16. Bargaining power of suppliers
17. Threat of new entrants
18. Threat of substitutes
19. Threat of rivalry
20. Market condition - Five forces 2019
21. Product - Market share 2019-2024 (%)
22. Comparison by Product
23. Artemisinin compounds - Market size and forecast 2019-2024 ($ million)
24. Artemisinin compounds - Year-over-year growth 2019-2024 (%)
25. Quinolines and related compounds - Market size and forecast 2019-2024 ($ million)
26. Quinolines and related compounds - Year-over-year growth 2019-2024 (%)
27. Other compounds - Market size and forecast 2019-2024 ($ million)
28. Other compounds - Year-over-year growth 2019-2024 (%)
29. Market opportunity by Product
30. Customer landscape
31. Market share by geography 2019-2024 (%)
32. Geographic comparison
33. APAC - Market size and forecast 2019-2024 ($ million)
34. APAC - Year-over-year growth 2019-2024 (%)
35. MEA - Market size and forecast 2019-2024 ($ million)
36. MEA - Year-over-year growth 2019-2024 (%)
37. South America - Market size and forecast 2019-2024 ($ million)
38. South America - Year-over-year growth 2019-2024 (%)
39. Europe - Market size and forecast 2019-2024 ($ million)
40. Europe - Year-over-year growth 2019-2024 (%)
41. North America - Market size and forecast 2019-2024 ($ million)
42. North America - Year-over-year growth 2019-2024 (%)
43. Key leading countries
44. Market opportunity by geography ($ million)
45. Impact of drivers and challenges
46. Vendor landscape
47. Landscape disruption
48. Industry risks
49. Vendors covered
50. Market positioning of vendors
51. AstraZeneca Plc - Overview
52. AstraZeneca Plc - Business segments
53. AstraZeneca Plc - Key offerings
54. AstraZeneca Plc - Key customers
55. AstraZeneca Plc - Segment focus
56. Bayer AG - Overview
57. Bayer AG - Business segments
58. Bayer AG - Key offerings
59. Bayer AG - Key customers
60. Bayer AG - Segment focus
61. Cipla Inc. - Overview
62. Cipla Inc. - Business segments
63. Cipla Inc. - Key offerings
64. Cipla Inc. - Key customers
65. Cipla Inc. - Segment focus
66. F. Hoffmann-La Roche Ltd. - Overview
67. F. Hoffmann-La Roche Ltd. - Business segments
68. F. Hoffmann-La Roche Ltd. - Key offerings
69. F. Hoffmann-La Roche Ltd. - Key customers
70. F. Hoffmann-La Roche Ltd. - Segment focus
71. GlaxoSmithKline Plc - Overview
72. GlaxoSmithKline Plc - Business segments
73. GlaxoSmithKline Plc - Key offerings
74. GlaxoSmithKline Plc - Key customers
75. GlaxoSmithKline Plc - Segment focus
76. Mylan NV - Overview
77. Mylan NV - Business segments
78. Mylan NV - Key offerings
79. Mylan NV - Key customers
80. Mylan NV - Segment focus
81. Novartis AG - Overview
82. Novartis AG - Business segments
83. Novartis AG - Key offerings
84. Novartis AG - Key customers
85. Novartis AG - Segment focus
86. Pfizer Inc. - Overview
87. Pfizer Inc. - Business segments
88. Pfizer Inc. - Key offerings
89. Pfizer Inc. - Key customers
90. Pfizer Inc. - Segment focus
91. Sanofi - Overview
92. Sanofi - Business segments
93. Sanofi - Key offerings
94. Sanofi - Key customers
95. Sanofi - Segment focus
96. Sun Pharmaceutical Industries Ltd. - Overview
97. Sun Pharmaceutical Industries Ltd. - Business segments
98. Sun Pharmaceutical Industries Ltd. - Key offerings
99. Sun Pharmaceutical Industries Ltd. - Key customers
100. Sun Pharmaceutical Industries Ltd. - Segment focus
101. Currency conversion rates for US$
102. Research Methodology
103. Validation techniques employed for market sizing
104. Information sources
105. List of abbreviations
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4

FEATURED COMPANIES

  • AstraZeneca Plc
  • Bayer AG
  • Cipla Inc.
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline Plc
  • Mylan NV
  • MORE
The publisher recognizes the following companies as the key players in the global anti-malarial medicines market: AstraZeneca Plc, Bayer AG, Cipla Inc., F. Hoffmann-La Roche Ltd., GlaxoSmithKline Plc, Mylan NV, Novartis AG, Pfizer Inc., Sanofi, and Sun Pharmaceutical Industries Ltd..

Commenting on the report, an analyst from the research team said:"The latest trend gaining momentum in the market is the enhanced poc diagnostics and biomarkers for malaria."

According to the report, one of the major drivers for this market is the strong funding to eradicate malaria.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Note: Product cover images may vary from those shown
5 of 4
  • AstraZeneca Plc
  • Bayer AG
  • Cipla Inc.
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline Plc
  • Mylan NV
  • Novartis AG
  • Pfizer Inc.
  • Sanofi
  • Sun Pharmaceutical Industries Ltd.
Note: Product cover images may vary from those shown
Adroll
adroll